You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Reduction in C-terminal amidated species of recombinant monoclonal antibodies by genetic modification of CHO cells
|
|---|---|
| Published in |
BMC Biotechnology, August 2014
|
| DOI | 10.1186/1472-6750-14-76 |
| Pubmed ID | |
| Authors |
Mihaela Škulj, Dejan Pezdirec, Dominik Gaser, Marko Kreft, Robert Zorec |
| Abstract |
During development of recombinant monoclonal antibodies in Chinese hamster ovary (CHO) cells, C-terminal amidated species are observed. C-terminal amidation is catalysed by peptidylglycine alpha-amidating monooxygenase (PAM), an enzyme known to be expressed in CHO cells. The significant variations between clones during clone selection, and the relatively high content of amidated species (up to 15%) in comparison to reference material (4%), led us to develop a cell line with reduced production of C-terminal amidated monoclonal antibodies using genetic manipulation. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 3 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 33% |
| Members of the public | 1 | 33% |
| Scientists | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 74 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 1% |
| France | 1 | 1% |
| Canada | 1 | 1% |
| Slovenia | 1 | 1% |
| Unknown | 70 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 28 | 38% |
| Student > Ph. D. Student | 12 | 16% |
| Student > Bachelor | 6 | 8% |
| Other | 4 | 5% |
| Student > Postgraduate | 4 | 5% |
| Other | 8 | 11% |
| Unknown | 12 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 32 | 43% |
| Biochemistry, Genetics and Molecular Biology | 13 | 18% |
| Immunology and Microbiology | 3 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 4% |
| Engineering | 3 | 4% |
| Other | 4 | 5% |
| Unknown | 16 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 September 2022.
All research outputs
#4,270,664
of 23,426,104 outputs
Outputs from BMC Biotechnology
#210
of 945 outputs
Outputs of similar age
#41,587
of 232,745 outputs
Outputs of similar age from BMC Biotechnology
#4
of 21 outputs
Altmetric has tracked 23,426,104 research outputs across all sources so far. Compared to these this one has done well and is in the 81st percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 945 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.8. This one has done well, scoring higher than 77% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 232,745 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.